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Rationale and design of a study exploring the
efficacy of once-daily oral rivaroxaban (X-TRA)
on the outcomeof left atrial/left atrial appendage
thrombus innonvalvularatrial fibrillationoratrial
flutter and a retrospective observational registry
providing baseline data (CLOT-AF)
Gregory Y. H. Lip, MD, a Christoph Hammerstingl, MD, b Francisco Marin, MD, c Riccardo Cappato, MD, d
Isabelle Ling Meng, MD, PhD, e Bodo Kirsch, MSc, f Eolo Morandi, MD, g Martin van Eickels, MD, e and
Ariel Cohen, MD, PhDh Birmingham, United Kingdom; Bonn, Berlin, Germany; Murcia, Spain; Milan, Italy; São Paulo,
Brazil; and Paris, FranceThere are still many unresolved issues concerning patient outcomes and prognostic factors in patients with atrial fibrillation (AF)
and left atrial/left atrial appendage (LA/LAA) thrombi. Rivaroxaban (Xarelto®), a potent and highly selective oral, direct factor
Xa inhibitor, is a new therapeutic option in this setting. The planned study program will consist of a prospective interventional
study (X-TRA) and a retrospective observational registry (CLOT-AF).
The primary objective of the X-TRA study is to explore the efficacy of rivaroxaban in the treatment of LA/LAA thrombi in patients
with nonvalvular AF or atrial flutter, scheduled to undergo cardioversion or AF ablation, in whom an LA/LAA thrombus has
been found on transesophageal echocardiography (TEE) before the procedure. The primary end point is the complete LA/LAA
thrombus resolution rate at 6 weeks of end of treatment confirmed by TEE. The secondary objectives are to describe categories
of thrombus outcome in patients (resolved, reduced, unchanged, larger, or new) confirmed on TEE at the end of treatment (after
6 weeks of treatment), incidence of the composite of stroke and noncentral nervous system systemic embolism at the end of
treatment and during follow-up, and incidence of all bleeding at the end of treatment and during follow-up.
The objective of the CLOT-AF registry is to provide retrospective thrombus-related patient outcome data after standard-of-care
anticoagulant treatment in patients with nonvalvular AF or atrial flutter, who have TEE-documented LA/LAA thrombi. The data
will be used as a reference for the prospective X-TRA study.
In conclusion, X-TRA and CLOT-AF will provide some answers to the many unresolved issues concerning patient outcomes and
prognostic factors in patients with AF and LAA thrombi. Results from this study program would provide the first prospective
interventional study (X-TRA) and a large international retrospective observational registry (CLOT-AF) on the prevalence and
natural history of LA/LAA thrombi. Unique data on clot resolution with rivaroxaban in a prospective cohort would be obtained
in X-TRA. (Am Heart J 2015;169:464-471.e2.)Atrial fibrillation (AF) predisposes to the development of
atrial thrombi, most commonly in the left atrial (LA)
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et-Marie-Curie, Saint-Antoine University and Medical School, Paris, France.(N90%) in nonvalvular AF.1 Poor-quality anticoagulation,
especially where time in therapeutic range (international
normalized ratio [INR] 2.0-3.0) is poor or beforehttp://dx.doi.org/10.1016/j.ahj.2014.12.020
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Volume 169, Number 4establishment of effective oral anticoagulation, is
associated with an increase in the risks of stroke and
thromboembolism.2,3 Unresolved thrombi in the LAA
(identified in 10% of patients with AF and at high risk of
thromboembolism) may result in an increased subse-
quent risk of thromboembolic events.4-6 For example,
during the initial control phase of the Ludwigshafen
Observational Cardioversion Study, in the conventional
approach (using transesophageal echocardiography),
LA/LAA thrombus was found in the left atrium in 7.7%
of cases, and 3 thromboembolic events occurred in the
first 4 weeks after cardioversion (CV) (0.8%), a rate
similar to that observed in the prospective TEE group.7
Transesophageal echocardiography is well established as
the criterion standard for evaluation of the LA/LAA for the
presence of thrombi.8-11 If an LA/LAA thrombus is detected
during TEE evaluation, current AF guidelines include
treatment with vitamin K antagonist (VKA) therapy for
3weeks,with an INR ranging from2.0 to 3.0.12 A follow-up
TEE assessment at 3 weeks is recommended to ensure
thrombus resolution.12
Cardioversion is one of the therapeutic options used to
restore sinus rhythm; however, the procedure may
result in dislodgment of LA thrombi or lead to new
thrombus formation owing to atrial stunning after CV
and is associated with an increased risk of stroke.4,13,14 A
treatment option is to perform immediate CV in patients
with symptomatic AF after exclusion of LA thrombi with
TEE under effective anticoagulation with short-acting
anticoagulants. After a median of 4 weeks on warfarin
therapy, the resolution rates of the thrombi on TEE were
reported to be approximately 50% to 90%.4,7,9,14-16 The
wide range of resolution rates was caused by different
populations (eg, those that did or did not include
valvular AF; first diagnosed or persistent AF), different
anticoagulation, and/or imaging strategies evaluated in
relatively small observational studies.
Owing to the low incidence of LA/LAA thrombi in
patients with AF, data are limited. In ROCKET AF, 321
patients underwent a total of 460 CV or AF ablation
procedures.17 Only small retrospective or prospective
observational studies have been published (online
Appendix Supplementary Table I). In a post hoc analysis
of the ARISTOTLE trial, no LA thrombi were found in 171
patients who underwent TEE.18
Data for the non-VKA oral anticoagulants (NOACs)
(previously called new or novel OACs) are presently
limited19 with regard to the treatment and outcome of
patients with AF and LA/LAA thrombus, and these data
largely comprise case reports. Non-VKA oral anticoagu-
lants may offer several advantages in their relative
efficacy, safety, and convenience as well as fast onset
of therapeutic anticoagulation, when LA/LAA thrombus
is detected.20,21
Several case reports indicate favorable outcomes in
thrombus patients treated with NOACs, in which VKAsfailed to resolve LA thrombi. In 1 case, LAA thrombus was
resolved after 7 weeks' treatment with dabigatran. This
patient failed to achieve INR N2 after 2 weeks of dose-
adjusted VKA therapy before switching to dabigatran.22
Results of a preliminary publication have shown that,
among 487 patients undergoing TEE before electrical CV
or before AF ablation, when stratified by type of
anticoagulation, dabigatran use was associated with a
4.6-times higher likelihood of LAA thrombi compared
with warfarin (odds ratio 4.6 [1.6-21] P = .003) and 6.2-
times higher likelihood compared with rivaroxaban
(odds ratio 6.2 [1.9-31] P = .002).23 After 4 weeks'
treatment with rivaroxaban 15 mg once daily in a 64-year-
old man, TEE showed a decrease in thrombus size; 6
weeks' treatment resulted in complete resolution of the
LAA thrombus.24 In addition, Takasugi et al25 described a
set of 3 cases in which patients with nonvalvular AF-
related stroke had resolution of LAA thrombi within 8 to
33 days of rivaroxaban treatment. Apixaban was also
shown to completely resolve LA thrombus in a 72-year-
old man, after 16 days of treatment.26 In an 86-year-old
man, 11 weeks of apixaban therapy led to almost
complete resolution of LA thrombus.27 Studies examining
TEE detection and thrombus resolution are described in
online Appendix Supplementary Table I.
It is possible that the potential mechanism of action
of NOACs allows for relatively higher thrombus
resolution rates compared with the VKAs.28 The current
published case reports encourage further investigations
in this field.Rationale
There are still many unresolved issues concerning patient
outcomes and prognostic factors in patients with AF and
LA/LAA thrombi. Rivaroxaban, a potent and highly
selective, oral, direct factor Xa inhibitor, is a new
therapeutic option in this setting.29 The planned study
program will consist of a prospective interventional study
(X-TRA; Xarelto – ThRombus Accelerated resolution) and a
retrospective observational registry (CLOT-AF). The CLOT-
AF registrywas developed in light of the limited data on the
prevalence and natural history of LA/LAA thrombi, and we
wished to acquire center-specific data from the study sites
undertaking X-TRA.Study objectives and end points
X-TRA
The primary objective of this study (ClinicalTrials.gov
identifier NCT01839357) is to explore the efficacy of
rivaroxaban in the treatment of LA/LAA thrombi in patients
with nonvalvular AF or atrial flutter, scheduled to undergo
CV or AF ablation, in whom an LA/LAA thrombus has been
found on TEE before procedure. The primary end point is
the complete LA/LAA thrombus resolution rate at 6 weeks
Figure 1
X-TRA study design. CrCl, creatinine clearance; od, once daily.
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valvular AF is used to imply that AF is not related to
rheumatic valvular disease (predominantly mitral stenosis)
or prosthetic heart valves.21
The secondary objectives of the study are to describe
categories of thrombus outcome in patients (resolved,
reduced, unchanged, larger, or new) confirmed on TEE at
the end of treatment (after 6 weeks of treatment),
incidence of the composite of stroke and noncentral
nervous system systemic embolism at the end of
treatment and during follow-up, and incidence of all
bleeding (major and nonmajor) events at the end of
treatment and during follow-up.
The exploratory objectives of the study in theVKA/NOAC
naive/untreated subgroup are to evaluate biomarkers of
prothrombotic status (plasma prothrombin fragment 1 + 2
and thrombin-antithrombin complexes), inflammatory re-
sponse (high-sensitivity interleukin 6 [IL-6]; high-sensitivity
C-reactive protein), thrombogenesis (D-dimers), fibrinolysis
(plasminogen activator inhibitor type 1 [PAI-1] antigen),
and endothelial damage/dysfunction (von Willebrand
factor [vWF]).
CLOT-AF
The objective of this registry (ClinicalTrials.gov identifier
NCT01928979) is to provide retrospective thrombus-
related patient outcome data after standard-of-care
anticoagulant treatment in patients with nonvalvular
AF or atrial flutter, who have TEE-documented LA/LAA
thrombi. The data will be used as a reference for the
prospective X-TRA study.
The primary outcome of interest is thrombus resolution
rate confirmed on TEE after 3 to 12 weeks of anticoagulant
treatment based on the routine practice of the centers.
Secondary end points are stroke or noncentral nervous
system systemic thromboembolism rate and all bleeding
(major, nonmajor, and unknown severity) rates.External data evaluation bodies
X-TRA
A steering committee will be involved periodically in
the planning, review, oversight of design, conduct, and
study progress. The study outcome committee (SOC) will
apply the protocol definitions (to be provided in the SOC
manual) and will centrally adjudicate TEE results in a
blinded fashion regarding pretreatment or posttreatment,
but will not otherwise be involved in the study.
Assessment of the SOC is the basis for the analysis of
the efficacy end point.
CLOT-AF
In a subset of patients (≥20% of sites), source data
verification will be conducted. The purpose is to review
documented data for completeness and plausibility,
adherence to study protocol, and verification with source
documents. Depending on the local, legal, and ethical
regulations as well as data protection laws, the reviewer
will compare data in the case report form with data in
the source. Transesophageal echocardiography data in
CLOT-AF will not be centrally adjudicated.
Study design
X-TRA
The X-TRA study is a prospective, single-arm, open-
label, multicenter study. Owing to the expected low
incidence of LA/LAA thrombi in patients with AF, the
proposed study will be explorative in nature but will be
the first prospective interventional study with a NOAC in
this setting.
The study will be designed as described in Figure 1. At
the end of the treatment period, TEE will be repeated and
centrally adjudicated by the SOC. An additional TEE
should be encouraged at the posttreatment follow-up visit
for patients with residual thrombi.
Figure 2
Overview of CLOT-AF registry. FPFV, first patient, first visit; LPFV, last patient, first visit; LPLV, last patient, last visit.
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CLOT-AF, a retrospective registry independent from
the prospective interventional study, is planned in
parallel to collect baseline data and outcome information
from patients with nonvalvular AF or atrial flutter who
received VKA treatment based on standard of care and
have LA/LAA thrombus confirmed on TEE. This retro-
spective registry will be set up at the same study sites
participating in the X-TRA study to collect thrombus
outcome data during 2011 to 2012 as a historical baseline
of standard of care.
Retrospective patient data were collected from May
2013 to May 2014. The observation of each patient covers
the period from the diagnosis of an LA/LAA thrombus
until the end-of-treatment TEE after the 3- to 12-week
standard-of-care anticoagulation therapy (Figure 2). If no
end-of-treatment TEE has been performed during 3 to 12
weeks of anticoagulant therapy, the observational period
will end at 12 weeks after diagnosis, at the latest. If N1 TEE
was performed during treatment, the thrombus outcome
will be collected from the last TEE performed within 12
weeks of treatment start.
Eligible patients during the period from January 1, 2011
to December 31, 2012 are to be identified via screening
and review of medical records, for inclusion in registry.
This retrospective screening and review will occur
between May 2, 2013 and May 2, 2014. The observation
of each patient will cover the period from diagnosis of an
LA/LAA thrombus until the end-of-treatment TEE after the
3- to 12-week standard-of-care anticoagulation therapy.
Ethics approval
For both X-TRA and CLOT-AF, documented approval
from the appropriate independent ethics committees/
institutional review boards will be obtained for all
participating centers before the start of the study
according to good clinical practice and local laws,
regulations, and organizations.Patient population
X-TRA study
Men or women aged ≥18 years with hemodynamically
stable nonvalvular AF or atrial flutter in whom LA/LAA
thrombus has been documented at baseline by TEE up to
72 hours before the start of study drug treatment are
eligible for inclusion. Eligible patients must be VKA/NOAC
naive or untreated within 1 month before signing the
informed consent form (treatment of up to 72 hours with
VKA, heparin, or a low molecular weight heparin is
allowed before the start of study drug treatment) or
VKA pretreated but under ineffective INR levels (b2.0
documented with ≥2 consecutive measurements that are
≥24 hours apart) within the last 6 weeks.
Patients who meet any of the following cardiac-related
criteria will be excluded: previous intracardiac thrombus,
free-floating ball thrombus, intracardiac tumor (eg, known
presence of atrial myxoma), known left ventricular or
aortic thrombus, or active endocarditis. Patients with
the following will be also excluded: calculated creatinine
clearance b15 mL/min at the screening visit, hepatic
disease that is associated with coagulopathy leading to a
clinically relevant bleeding risk, or any severe condition
that would limit life expectancy to b3 months (eg,
advanced malignancy). Complete inclusion and exclusion
criteria are described in online Appendix Supplementary
Table II.
CLOT-AF
Men or women aged ≥18 years with hemodynamically
stable nonvalvular AF or atrial flutter in whom LA/LAA
thrombus has been documented at baseline by TEE are
eligible for inclusion.
Patients who meet any of the following cardiac-related
criteria will be excluded: valvular AF (European Society of
Cardiology 2012 definition),21 a history of cardiac throm-
bus confirmed on TEE, intracardiac tumors (eg, known
presence of atrial myxoma), or active endocarditis.
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X-TRA study
Patients will be treated with 6 weeks of rivaroxaban
20 mg once daily, with a dose reduction to 15 mg once
daily for patients with moderate-to-severe renal impair-
ment (ie, creatinine clearance of 15-49 mL/min; inclusive)
at screening.
CLOT-AF registry
Owing to the retrospective, observational nature of the
CLOT-AF registry, the choice of anticoagulant was left to
the discretion of the treating physician.
Transesophageal echocardiography
Transesophageal echocardiography will be performed
according to standard procedures at screening and at the
end of treatment. If a residual or new thrombus is
confirmed on the end-of-treatment TEE, performance of
an additional TEE should be encouraged at the end of the
follow-up period. Transesophageal echocardiography
data obtained before the screening visit will be collected
on DVD or in electronic format for review by the SOC as
baseline. In the X-TRA study, TEE images will be recorded
by the investigator for the SOC to adjudicate the primary
end point and confirm the presence of a thrombus. The
results of the third TEE (if performed) will be reported in
the electronic case report form by the investigators.
Data to be collected include number, size, location,
mobility of thrombus/thrombi for primary outcome, and
evolution of the LA/LAA thrombus, for example,
resolved, reduced in size, stable (unchanged size), or
worsened (increased in size or new thrombus). All
examinations should be recorded for adjudication and
to differentiate thrombus from severe (“sludge”) left atrial
spontaneous echo contrast.
Biomarkers
The effect of rivaroxaban will be explored in the study
population with respect to coagulation, inflammatory
response, fibrinolysis, and endothelial damage/dysfunction.
A blood sample will be obtained only in the VKA/NOAC
naive/untreated subgroup at screening and at the end of
treatment (or at the time of early discontinuation of study
drug treatment if blood sampling can occur within 24 hours
after the last dose of study drug).
In several studies, coagulation biomarkers, such as
fibrin D-dimers, were elevated in patients with AF and
those with LA thrombi.30-33 A sufficient anticoagulant
effect is mirrored by a significant decrease of coagulation
biomarkers.34,35 Left atrial thrombi presence is associated
with elevated plasma C-reactive protein levels,36 and the
proinflammatory cytokine IL-6 is suspected to have a role
in thrombogenesis.37,38 It has been shown that plasma IL-
6 levels are related to markers of prothrombotic state of
patients with AF.30 Plasminogen activator inhibitor type 1inhibits endogenous fibrinolysis, and plasma PAI-1 levels
are increased in patients with AF.39 Expression of PAI-1
has been shown to be upregulated in the left atrium in AF
and could have a role in thrombogenesis.40 Further
investigations revealed that PAI-1 decreases significantly
upon anticoagulation therapy.41
Plasma vWF plays an important role in platelet adhesion
to the subendothelium. Furthermore, vWF regulates
thrombus formation by interacting with glycoprotein
complexes.42 It is an established biomarker of endothelial
damage and/or dysfunction. It was found that high vWF
was associated with future adverse cardiovascular events
and mortality in patients with permanent AF.43 Patients
with AF and LAA thrombus had higher vWF antigen
activity compared with those without LAA thrombus.44
Several other studies have emphasized the use of plasma
vWF to stratify risk and predict outcome in AF.45,46
Statistical analysis plan
Statistical analyses will be exploratory and descriptive
and are not powered to test any specific hypothesis. The
estimated sample size is based on the expected presence of
an LA/LAA thrombus detected on TEE in the study sites
participating in the enrollment period. The reported
incidence of LA/LAA thrombus is varied and low, in the
region of 5% to 15%.12 Online Appendix Supplementary
Table I describes the incidence of LA/LAA thrombus in
published literature, with most studies identifying LA/LAA
thrombi in b60 patients. One study identified LAA thrombi
in 151 of 9,058 patients. Therefore, it is determined that the
target enrollment for theX-TRA study is 60patients.With 60
evaluable subjects the width of the 95% CI for the primary
variable is expected to be 0.26 (26 percentage points) or
less depending on the observed resolution rate.
The primary outcome measure is the complete resolu-
tion of LA/LAA thrombus. This will be evaluated on a per-
patient basis. The definition of complete thrombus
resolution for a patient refers to being completely
thrombus free in the left atrium. This will be based on
the end-of-treatment TEE as determined by independent
adjudication by the SOC. The primary analysis will evaluate
this outcome on the modified intent-to-treat population
(patients with LA thrombus at baseline who have an
evaluable end-of-treatment TEE after 6weeks of treatment).
Sensitivity analysis of the primary outcome will be based
on the intent-to-treat population, inwhich patients without
an evaluable TEEwill be considered to still have a thrombus
in this summary. Exact (Clopper-Pearson) 95% CIs for
the probability of a present thrombus in the LA/LAA will
be calculated.
The secondary outcome measure will evaluate the
outcome of thrombi after 6 weeks' treatment relative to
patients observed at study entry. For this evaluation,
patients will be categorized according to the worst change
in thrombus noted on the end-of-treatment TEE compared
with the baseline TEE. Individual thrombi will be evaluated
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unchanged, or enlarged since baseline or new as compared
with baseline, and patientswill be categorized according to
the most severe category into which any thrombus falls.
Rates will be provided for each category, and 95% CIs
for the probability of belonging to the combined categories
of resolved/reduced and unchanged/enlarged/new will
be calculated.
Discussion
Non-VKA oral anticoagulants are increasingly being used
for the prevention and treatment of thrombi formation
owing to the inherent limitations of VKAs, such as difficulty
in maintaining patients within a narrow therapeutic
range and the need for regular INR measurements.47,48
The NOACs work by directly inhibiting either thrombin
or factor Xa, reducing thrombus formation. The differences
in the mechanisms of action may be a factor in resolution
of LA/LAA thrombi in patients with AF. Direct thrombin
inhibitors such as dabigatran prevent thrombin from
activating fibrinogen into fibrin. Conversely, rivaroxa-
ban, apixaban, and edoxaban target factor Xa, prevent-
ing it from activating prothrombin to thrombin. Factor
Xa is considered to be a particularly appropriate target
for thrombus inhibition because of its convergent
position between the intrinsic and extrinsic coagulation
pathways,49 with 1 molecule of factor Xa also responsi-
ble for the generation of N1000 thrombinmolecules.50 In
addition, direct thrombin inhibitors may downregulate
protein C to a greater extent than factor Xa inhibitors51
and consequently downregulate protein C-mediated
anticoagulant pathways.52
X-TRA and CLOT-AF will provide some answers to the
many unresolved issues concerning patient outcomes and
prognostic factors in patients with AF and LAA thrombi.
Results from this study program would provide the first
data on the prevalence and natural history of LA/LAA
thrombi. In addition, unique data on clot resolution with
rivaroxaban in a prospective cohort would be obtained
in X-TRA.
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Volume 169, Number 4AppendixSupplementary Table I. Published studies on LA/LAA thrombus on echocardiography and resolution with anticoagulation
Study Anticoagulant Findings
Akdeniz et al53 (observational) Warfarin (target INR 2.0-3.0) • Thrombus was observed in 32 (15.4%) of 208 patients after 4-6 wk of warfarin therapy
• Of the 11 patients who underwent a control TEE, 7 (63.6%) exhibited
thrombus resolution
Collins et al15 (observational) Warfarin (target INR 2.0-2.8) • Thrombus resolution in 86% of patients with AF after 4 wk of warfarin therapy
Seidl et al17 (single-center
observational)
Warfarin (target INR 2.0-3.0) • Thrombus was observed in the left atrium of 55 (7.7%) of the 719 patients in the
TEE-guided group
• All 55 patients had their INR increased to 3-3.5 for 4 wk, and resolution of the LA
thrombus was detected on TEE in 55% of patients
• Low resolution rate explained partially by the inclusion of patients with valvular AF
(nearly one-third of study population)
Corrado et al4 (observational) Warfarin (target INR ≥2) • Resolution of atrial thrombi after 4 wk of warfarin therapy in 9 (81.8%) of 11 patients
(95% CI 48.2-97.7%)
Jaber et al16 (observational) Warfarin (mean INR 2.2) or heparin • 174 patients with thrombi in LAC and LAA. 161 patients received anticoagulant
therapy for 47 ± 18 d
• 80% success in resolving LAC and LAA thrombi as demonstrated by follow-up TEE.
Better success in resolving LAA thrombi (82.5%) vs LAC thrombi (53.3%)
Fukuda et al54 (observational) Warfarin (target INR ≥2) • 148 patients on warfarin therapy for N3 wk with subtherapeutic anticoagulation
(INR 1.9 ± 0.7)
• LA thrombus was observed on TEE in 13 (8.8%) patients with nonvalvular AF
• LA thrombus was observed in 3 (3.6%) of 83 patients with sufficient
anticoagulation (N3 wk)
Nagarakanti et al5 (RE-LY,
post hoc analysis)
Dabigatran 110 mg bid (D110);
dabigatran 150 mg bid (D150);
warfarin
• 165 patients on D110 therapy, 162 patients on D150 therapy, and 88 patients on
warfarin therapy were assessed using TEE
• 1.8% of D110 patients, 1.2% of D150 patients, and 1.1% of warfarin patients were
positive for LA thrombi
• Thrombus resolution not reported
Vidal et al22 (case study) Dabigatran 150 mg bid • 59-year-old White woman had LAA thrombus detected by TEE
• Unable to achieve therapeutic INR with warfarin therapy so switched to dabigatran
• Resolution of thrombus achieved after 7 wk of dabigatran treatment
Hammerstingl et al24 (case study) Rivaroxaban 15 mg od • 64-year-old man with LAA thrombus detected by TEE
• 4 wk of treatment with rivaroxaban was associated with decrease in thrombus size
• Complete thrombus resolution was identified after 6 wk of therapy
Takasugi et al25 (case study) Rivaroxaban 10 mg od • 3 patients (2 males, 1 female) had presence of LAA thrombi detected by TEE
• Treatment with rivaroxaban led to resolution of thrombus within 8-33 d
• 2 patients had resolution after 8 d of therapy, with the other patient showing a
reduction in thrombus size after 21 d and resolution after 33 d of therapy
Kawakami et al26 (case study) Apixaban 5 mg bid • 72-year-old man with LAA thrombus identified by TEE
• 16 d of apixaban treatment led to complete thrombus resolution
Dobashi et al27 (case study) Apixaban 2.5 mg bid • 86-year-old man with LA thrombus detected through TEE
• 11 wk of apixaban treatment resulted in almost complete thrombus resolution
Abbreviations: bid, twice daily; od, once daily; LAC, left atrial cavity.
Supplementary Table II. Inclusion/exclusion criteria for X-TRA study
Inclusion criteria:
• Men or women aged ≥18 y
• Hemodynamically stable nonvalvular AF or atrial flutter
• LA/LAA thrombus documented at baseline by TEE up to 72 h before the start of study drug treatment
• VKA/NOAC naive or untreated within 1 m before signing the informed consent form (treatment of up to 72 h with VKA, heparin, or a low molecular
weight heparin is allowed before the start of study drug treatment)
or
• VKA pretreated but under ineffective INR levels (b2.0 documented with ≥2 consecutive measurements ≥24 h apart) within last 6 wk
• Written informed consent
•Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies from signing of informed consent
form until 30 d after the last study drug administration
Exclusion criteria:
• TIA within 3 d before study inclusion
• Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 m or any stroke within 14 d before start of study drug
• Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 d before study inclusion
• Acute MI within the last 14 d before study inclusion
• Cardiac-related criteria
- Previous intracardiac thrombus
- Free-floating ball thrombus55,56
- Intracardiac tumor, eg, known presence of atrial myxoma
- Known left ventricular or aortic thrombus
- Active endocarditis15
• Active bleeding or high risk of bleeding contraindicating anticoagulant therapy
• Concomitant drugs/therapies
- Indication for anticoagulant therapy for a condition other than nonvalvular AF or atrial flutter, eg, VTE
- Concomitant use of anticoagulant drugs, including VKA or factor IIa or factor Xa inhibitors
- Chronic ASA therapy N100 mg daily or dual antiplatelet therapy
- Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, ie, all HIV protease inhibitors and the following azole antimycotics agents:
ketoconazole, itraconazole, voriconazole, and posaconazole—if used systemically
• Concomitant conditions
- Childbearing potential without proper contraceptive measures, pregnancy, or breastfeeding
- Hypersensitivity to investigational treatment
- Calculated CrCl b15 mL/mina at the screening visit
- Coagulopathy-associated hepatic disease leading to clinically relevant bleeding risk; any severe condition that would limit life expectancy to b3 m such
as advanced malignancy
- Planned invasive procedure with potential for uncontrolled bleeding or increased risk of stroke, including major surgery, cardiac catheterization, or CV
before the end-of-treatment TEE
- Inability to take oral medication
- Ongoing drug addiction or alcohol abuse
• Any other contraindication listed in accordance with local marketing regulations for the experimental treatment
• Participation in a study with an investigational drug or medical device within 30 d before start of study medication
• Previous assignment to treatment during this study
• Inability to cooperate with the study procedures
Abbreviations: ASA, Acetylsalicylic acid; CrCl, creatinine clearance; CYP, cytochrome P450; HIV, human immunodeficiency virus;MI, myocardial infarction; TIA, transient ischemic
attack; VTE, venous thromboembolism.
aCreatinine clearance calculated according to the Cockcroft-Gault formula.
471.e2 Lip et al
American Heart Journal
April 2015
